Phase II Study of Pembrolizumab and Itacitinib for Patients with Metastatic NSCLC Expressing PD-L1: Long-Term Follow up

被引：0

作者：

Marmarelis, M. E. ^{[1
]}

Cantor, D. J. ^{[1
]}

Mathew, D. ^{[1
]}

McWilliams, T. ^{[1
]}

Bauml, J. ^{[2
]}

Hwang, W-T ^{[1
]}

Singh, A. ^{[1
]}

D'Avella, C. ^{[1
]}

Davis, C. ^{[1
]}

Ye, D. ^{[1
]}

Sun, L. ^{[1
]}

Ciunci, C. ^{[1
]}

Aggarwal, C. ^{[1
]}

Cohen, R. B. ^{[1
]}

Minn, A. ^{[1
]}

Wherry, J. ^{[1
]}

Langer, C. J. ^{[1
]}

机构：

[1] Univ Penn, Philadelphia, PA USA

[2] Janssen, Philadelphia, PA USA

来源：

JOURNAL OF THORACIC ONCOLOGY | 2024年 / 19卷 / 10期

关键词：

Immunotherapy; JAK; Pembrolizumab;

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

OA06.04

引用

页码：S20 / S20

页数：1

共 50 条

[1] Phase II Study of Pembrolizumab and Itacitinib for First Line Treatment of Metastatic NSCLC Expressing PD-L1
Marmarelis, M. E.
Mathew, D.
Bauml, J. M.
Hwang, W. -T.
Zhang, J.
Singh, A.
D'Avella, C.
Davis, C.
Ye, D.
Sun, L.
Ciunci, C.
Zhang, N.
Aggarwal, C.
Cohen, R. B.
Minn, A. J.
Wherry, E. J.
Langer, C. J.
JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (09) : S122 - S123
[2] Long-term follow-up of anti-PD-1 naive patients with metastatic melanoma treated with IDO/PD-L1 targeting peptide vaccine and nivolumab
Lorentzen, Cathrine Lund
Kjeldsen, Julie Westerlin
Ehrnrooth, Eva
Andersen, Mads Hald
Svane, Inge Marie
JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2023, 11 (05)
[3] The effect of tumor size and metastatic extent on the efficacy of first line pembrolizumab monotherapy in patients with high PD-L1 expressing advanced NSCLC tumors
Schakenraad, Alexandra
Hashemi, Sayed
Twisk, Jos
Houda, Ilias
Ulas, Ezgi
Daniels, Johannes M. A.
Veltman, Joris
Bahce, I.
LUNG CANCER, 2021, 162 : 36 - 41
[4] Pembrolizumab Alone or Combined With Chemotherapy in Advanced NSCLC With PD-L1 ≥50%: Results of a Retrospective Study
Chen, Ya
Wang, Yanan
Yang, Zhengyu
Hu, Minjuan
Zhang, Yanwei
Qian, Fangfei
Zhang, Wei
Zhang, Bo
Han, Baohui
FRONTIERS IN ONCOLOGY, 2021, 11
[5] A Phase II Study of Selective AXL Inhibitor Bemcentinib and Pembrolizumab in Patients with NSCLC Refractory to Anti-PD(L)1
Krebs, M.
Brunsvig, P.
Helland, A.
Vinolas, N.
Aix, S.
Carcereny, E.
Domine Gomez, M.
Trigo Perez, J. M.
Arriola, E.
Garcia Campelo, R.
Spicer, J.
Thompson, J.
Ortega Granados, A. L.
Holt, R.
Smethurst, D.
Lorens, J.
Shoaib, M.
Siddiqui, A.
Schoelermann, J.
Lorens, K.
Schmidt, E.
Chisamore, M. J.
Felip, E.
JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S388 - S388
[6] Continuation of Pembrolizumab with Additional Chemotherapy after Progression with PD-1/PD-L1 Inhibitor Monotherapy in Patients with Advanced NSCLC: A Randomized, Placebo-Controlled Phase II Study
Jung, Hyun Ae
Park, Sehhoon
Choi, Yoon-La
Lee, Se-Hoon
Ahn, Jin Seok
Ahn, Myung-Ju
Sun, Jong-Mu
CLINICAL CANCER RESEARCH, 2022, 28 (11) : 2321 - 2328
[7] Cost-Effectiveness of Pembrolizumab as 1st Line Treatment for Metastatic NSCLC Patients with High PD-L1 Expression in Singapore
Tan, W. L.
Huang, M.
Chandwani, S.
Hsu, T.
Tan, S. C.
Tan, D.
JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S630 - S630
[8] Prognostic value of the Scottish Inflammatory prognostic Score in patients with NSCLC expressing PD-L1 ≥ 50 % progressing on first-line pembrolizumab
Stares, Mark
Doyle, Emma
Chapple, Sally
Raynes, George
MacDonald, James
Barrie, Colin
Laird, Barry
MacKean, Melanie
Philips, Iain
LUNG CANCER, 2024, 189
[9] Phase 3 Trofuse-007 Study: Sacituzumab Tirumotecan Plus Pembrolizumab vs Pembrolizumab Alone for NSCLC with PD-L1 TPS ≥50%
Frost, N.
Ghori, R.
Roy, A.
Nunes, A. T.
Yang, J. C. -H.
JOURNAL OF THORACIC ONCOLOGY, 2024, 19 (10) : S389 - S390
[10] 5-Year Survival of Pembrolizumab Plus Chemotherapy for Metastatic NSCLC With PD-L1 Tumor Proportion Score <1%
Gadgeel, S.
Rodriguez-Abreu, D.
Halmos, B.
Garassino, M. C.
Kurata, T.
Cheng, Y.
Jensen, E.
Shamoun, M.
Rajagopalan, K.
Paz-Ares, L.
JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S77 - S78

← 1 2 3 4 5 →